1. N6-methyladenosine (m6A) is the most common RNA modification and is thought to be a new epigenetic regulatory mechanism in RNA metabolism.
2. This study investigated the role of m6A in chemoresistance of colorectal cancer (CRC) by analyzing its mRNA expression profile and using m6A immunoprecipitation to determine its target.
3. Results showed that m6A demethylase FTO was upregulated in primary and 5-FU resistant CRC tissues, and its depletion reduced cell growth, colony formation, and metastasis of 5-FU resistant CRC cells in vitro and in vivo.
This article provides a comprehensive overview of the role of N6-methyladenosine (m6A) in chemoresistance of colorectal cancer (CRC). The authors present evidence from their own research as well as previous studies to support their claims, which makes the article reliable and trustworthy. The authors also provide detailed explanations for their findings, which further adds to the credibility of the article.
However, there are some potential biases that should be noted. For example, the authors focus mainly on how m6A can be used to improve CRC treatment through targeted epigenetic drugs, but they do not explore other possible treatments or counterarguments that could be used instead. Additionally, while the authors discuss potential risks associated with using m6A for treating CRC, they do not provide any evidence or data to back up these claims.
In conclusion, this article is generally reliable and trustworthy due to its comprehensive coverage of the topic as well as its use of evidence from both previous studies and current research conducted by the authors themselves. However, it does have some potential biases that should be taken into consideration when evaluating its trustworthiness and reliability.